Yes, Nuvisan offers clinical development consulting services across a broad range of areas. These include advice on specific scientific and regulatory questions, preparation and review of documents required for clinical trials in humans, and support for the design and refinement of clinical trials. Nuvisan also supports the transition from the preclinical to the clinical phase, including assessment of non-clinical requirements, calculation of the maximum recommended safe starting dose and definition of dose steps in first-in-human studies. In addition, Nuvisan provides broader regulatory consulting, including support for scientific advice procedures at national and European regulatory agencies, as well as preparation of integrated clinical development plans.